Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Several studies support the belief that the efficacy of adjuvant chemotherapy in breast cancer is related to the dose intensity of the chemotherapy used (expressed in milligrams per square meter per week). Retrospective analyses indicate that the actual delivered dose intensity may correlate more strongly with efficacy than the intended dose delivery. Methods. A doxorubicin-based adjuvant regimen was studied for breast cancer. It was modeled on the Southwest Oncology Group's regimen of cyclophosphamide, methotrexate, and 5-fluorouracil in that daily oral cyclophosphamide and weekly intravenous 5-fluorouracil were used, but weekly doxorubicin was substituted for methotrexate and administered in both the adjuvant and neoadjuvant setting to 29 patients. Results. The actual dose delivery was 1.21-1.24-fold that calculated for the delivered dose in the two other adjuvant regimens using the same three drugs (5-fluorouracil, doxorubicin, and cyclophosphamide) for which this could be determined. This regimen was tolerated well. Toxicity was minimal and consisted largely of expected neutropenia. Conclusions. Whether improved dose intensity can be increased further with the use of growth factors or actually confers improved outcomes awaits the results of larger future trials.

Original languageEnglish (US)
Pages (from-to)392-396
Number of pages5
JournalCancer
Volume71
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Methotrexate
Adjuvant Chemotherapy
Neutropenia
Intercellular Signaling Peptides and Proteins
Therapeutics
Drug Therapy
Pharmaceutical Preparations

Keywords

  • adjuvant chemotherapy
  • breast cancer
  • dose intensity
  • doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer. / Ellis, G.; Livingston, Robert B.

In: Cancer, Vol. 71, No. 2, 1993, p. 392-396.

Research output: Contribution to journalArticle

@article{49868a20bca243da82d8ddc6aee7a9ff,
title = "Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer",
abstract = "Background. Several studies support the belief that the efficacy of adjuvant chemotherapy in breast cancer is related to the dose intensity of the chemotherapy used (expressed in milligrams per square meter per week). Retrospective analyses indicate that the actual delivered dose intensity may correlate more strongly with efficacy than the intended dose delivery. Methods. A doxorubicin-based adjuvant regimen was studied for breast cancer. It was modeled on the Southwest Oncology Group's regimen of cyclophosphamide, methotrexate, and 5-fluorouracil in that daily oral cyclophosphamide and weekly intravenous 5-fluorouracil were used, but weekly doxorubicin was substituted for methotrexate and administered in both the adjuvant and neoadjuvant setting to 29 patients. Results. The actual dose delivery was 1.21-1.24-fold that calculated for the delivered dose in the two other adjuvant regimens using the same three drugs (5-fluorouracil, doxorubicin, and cyclophosphamide) for which this could be determined. This regimen was tolerated well. Toxicity was minimal and consisted largely of expected neutropenia. Conclusions. Whether improved dose intensity can be increased further with the use of growth factors or actually confers improved outcomes awaits the results of larger future trials.",
keywords = "adjuvant chemotherapy, breast cancer, dose intensity, doxorubicin",
author = "G. Ellis and Livingston, {Robert B}",
year = "1993",
doi = "10.1002/1097-0142(19930115)71:2<392::AID-CNCR2820710220>3.0.CO;2-Y",
language = "English (US)",
volume = "71",
pages = "392--396",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer

AU - Ellis, G.

AU - Livingston, Robert B

PY - 1993

Y1 - 1993

N2 - Background. Several studies support the belief that the efficacy of adjuvant chemotherapy in breast cancer is related to the dose intensity of the chemotherapy used (expressed in milligrams per square meter per week). Retrospective analyses indicate that the actual delivered dose intensity may correlate more strongly with efficacy than the intended dose delivery. Methods. A doxorubicin-based adjuvant regimen was studied for breast cancer. It was modeled on the Southwest Oncology Group's regimen of cyclophosphamide, methotrexate, and 5-fluorouracil in that daily oral cyclophosphamide and weekly intravenous 5-fluorouracil were used, but weekly doxorubicin was substituted for methotrexate and administered in both the adjuvant and neoadjuvant setting to 29 patients. Results. The actual dose delivery was 1.21-1.24-fold that calculated for the delivered dose in the two other adjuvant regimens using the same three drugs (5-fluorouracil, doxorubicin, and cyclophosphamide) for which this could be determined. This regimen was tolerated well. Toxicity was minimal and consisted largely of expected neutropenia. Conclusions. Whether improved dose intensity can be increased further with the use of growth factors or actually confers improved outcomes awaits the results of larger future trials.

AB - Background. Several studies support the belief that the efficacy of adjuvant chemotherapy in breast cancer is related to the dose intensity of the chemotherapy used (expressed in milligrams per square meter per week). Retrospective analyses indicate that the actual delivered dose intensity may correlate more strongly with efficacy than the intended dose delivery. Methods. A doxorubicin-based adjuvant regimen was studied for breast cancer. It was modeled on the Southwest Oncology Group's regimen of cyclophosphamide, methotrexate, and 5-fluorouracil in that daily oral cyclophosphamide and weekly intravenous 5-fluorouracil were used, but weekly doxorubicin was substituted for methotrexate and administered in both the adjuvant and neoadjuvant setting to 29 patients. Results. The actual dose delivery was 1.21-1.24-fold that calculated for the delivered dose in the two other adjuvant regimens using the same three drugs (5-fluorouracil, doxorubicin, and cyclophosphamide) for which this could be determined. This regimen was tolerated well. Toxicity was minimal and consisted largely of expected neutropenia. Conclusions. Whether improved dose intensity can be increased further with the use of growth factors or actually confers improved outcomes awaits the results of larger future trials.

KW - adjuvant chemotherapy

KW - breast cancer

KW - dose intensity

KW - doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=0027397472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027397472&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19930115)71:2<392::AID-CNCR2820710220>3.0.CO;2-Y

DO - 10.1002/1097-0142(19930115)71:2<392::AID-CNCR2820710220>3.0.CO;2-Y

M3 - Article

VL - 71

SP - 392

EP - 396

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -